CRISPR Therapeutics (NASDAQ:CRSP) PT Lowered to $60.00 at Royal Bank of Canada
CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its price target cut by Royal Bank of Canada from $66.00 to $60.00 in a research note released on Tuesday, Benzinga reports. They currently have a sector perform rating on the stock. CRSP has been the topic of several other research reports. Stifel Nicolaus reduced their price target […]
More Stories
Knowles (NYSE:KN) Updates Q3 2024 Earnings Guidance
Knowles (NYSE:KN – Get Free Report) issued an update on its third quarter 2024 earnings guidance on Thursday morning. The...
Fidelity Disruptive Finance ETF (FDFF) To Go Ex-Dividend on September 20th
Fidelity Disruptive Finance ETF (NASDAQ:FDFF – Get Free Report) declared a quarterly dividend on Thursday, September 19th, NASDAQ reports. Shareholders...
Rezolute (NASDAQ:RZLT) Releases Quarterly Earnings Results, Misses Expectations By $0.14 EPS
Rezolute (NASDAQ:RZLT – Get Free Report) posted its earnings results on Thursday. The company reported ($0.44) earnings per share (EPS)...
MillerKnoll (NASDAQ:MLKN) Issues FY25 Earnings Guidance
MillerKnoll (NASDAQ:MLKN – Get Free Report) issued an update on its FY25 earnings guidance on Thursday morning. The company provided...
Lennar (NYSE:LEN) Updates Q4 2024 Earnings Guidance
Lennar (NYSE:LEN – Get Free Report) issued an update on its fourth quarter 2024 earnings guidance on Friday morning. The...
Insider Selling: Rent the Runway, Inc. (NASDAQ:RENT) Insider Sells $13,940.00 in Stock
Rent the Runway, Inc. (NASDAQ:RENT – Get Free Report) insider Sarah K. Tam sold 1,394 shares of the stock in...